MarketCap
Facebook
X
Telegram
Travere Therapeutics Balance Sheet 2025-2011 | TVTX
Brief overview of Travere Therapeutics's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
The asset base decreased -22.1%, from $776.6 million to $605.2 million. Resources became smaller over the five periods.
Liability growth of +3.3% exceeded asset growth of -22.1%, increasing reliance on outside funding.
The equity ratio equals 19%, with a starting level of 38.9%. Stable cash flow is important under this structure.
Net debt stands at $224.6 million, or 1.96x of equity. The debt cushion is limited.
The cash reserve occupies 15.4% of the balance sheet, previously 21.3%. It is one marker of short-term resilience.
Retained earnings are negative at -$1.5 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Balance sheet takeaway
Travere Therapeutics's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Travere Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
225 M | 257 M | 324 M | 318 M | 64.7 M | 131 M | 142 M | 115 M | -54.3 M | 3.42 M | 6.1 M | 65.6 M | -6 M | 21.1 K | 21 K |
Long Term Debt |
312 M | 310 M | 377 M | 376 M | 227 M | 215 M | 205 M | 195 M | 45.1 M | 44.4 M | 43.9 M | 43.3 M | - | - | - |
Long Term Debt Current |
5.88 M | 5.4 M | 4.91 M | 4.43 M | 3.91 M | 357 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 288 M | 286 M | 142 M | 134 M | 127 M | 65.2 M | 3.6 M | - | - |
Total Current Liabilities |
160 M | 201 M | 178 M | 142 M | 124 M | 92.7 M | 95.4 M | 105 M | 85.7 M | 83.3 M | 85.8 M | 108 M | 36.6 M | 5.8 M | 556 K |
Total Liabilities |
490 M | 535 M | 588 M | 630 M | 475 M | 396 M | 384 M | 391 M | 227 M | 218 M | 212 M | 173 M | 38.8 M | 67 K | 64.2 K |
Deferred Revenue |
- | - | - | 12 M | 16.3 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.47 B | -1.45 B | -1.13 B | -1.01 B | -766 M | -586 M | -416 M | -270 M | -178 M | -113 M | -65.2 M | -179 M | -67.4 M | -136 K | -121 K |
Total Assets |
605 M | 594 M | 789 M | 673 M | 777 M | 607 M | 605 M | 709 M | 520 M | 525 M | 512 M | 135 M | 20.5 M | 3.91 K | 3.96 K |
Cash and Cash Equivalents |
93 M | 58.5 M | 58.2 M | 61.7 M | 166 M | 84.8 M | 62.4 M | 103 M | 99.4 M | 41 M | 37.8 M | 18.2 M | 6 M | 11.4 K | 10.1 K |
Book Value |
115 M | 59.1 M | 201 M | 42.9 M | 302 M | 211 M | 221 M | 318 M | 293 M | 308 M | 300 M | -37.3 M | -18.3 M | -63.1 K | -60.3 K |
Total Shareholders Equity |
115 M | 59.1 M | 201 M | 42.9 M | 302 M | 211 M | 221 M | 318 M | 293 M | 308 M | 300 M | -37.3 M | -19.7 M | -3.41 M | -536 K |
All numbers in USD currency
Quarterly Balance Sheet Travere Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
311 M | 311 M | 310 M | 310 M | 378 M | 378 M | 377 M | 377 M | 376 M | 376 M | 376 M | 375 M | - | 374 M | 227 M | 224 M | 221 M | 218 M | 215 M | 215 M | 215 M | 215 M | 205 M | 205 M | 205 M | 205 M | 195 M | 22.6 M | 195 M | 195 M | 45.1 M | 45.1 M | 45.1 M | - | 44.4 M | - | - | - | 43.8 M | 46 M | 91 M | 91 M | 43.3 M | 91 M | 91 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
523 M | 516 M | 535 M | 535 M | 536 M | 589 M | 588 M | 553 M | 620 M | 619 M | 630 M | 626 M | - | 620 M | 475 M | 468 M | 414 M | 401 M | 396 M | 396 M | 396 M | 396 M | 384 M | 384 M | 384 M | 384 M | 391 M | 391 M | 391 M | 391 M | 227 M | 227 M | 227 M | 227 M | 218 M | 218 M | 218 M | 218 M | 212 M | 212 M | 212 M | 212 M | 173 M | 173 M | 173 M | 173 M | 40.2 M | 38.8 M | 38.8 M | 38.8 M | 5.8 M | - | - | 5.8 M | - | - | - | - |
Deferred Revenue |
- | - | - | 3.8 M | 5.38 M | 6.46 M | 7.1 M | 8.96 M | 10.2 M | 11 M | 12 M | 11.4 M | - | 14.2 M | 16.3 M | 16.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.5 B | -1.49 B | -1.45 B | -1.39 B | -1.33 B | -1.26 B | -1.13 B | -1.04 B | -1.19 B | -1.1 B | -1.01 B | -948 M | - | -812 M | -766 M | -714 M | -679 M | -640 M | -586 M | -586 M | -586 M | -586 M | -416 M | -416 M | -416 M | -416 M | -270 M | -270 M | -270 M | -270 M | -178 M | -178 M | -178 M | -178 M | -113 M | -113 M | -113 M | -113 M | -65.2 M | -65.2 M | -65.2 M | -65.2 M | -179 M | -179 M | -179 M | -179 M | -68.2 M | -67.4 M | - | - | -33.6 M | -33.6 M | -140 K | -136 K | -132 K | - | - | -121 K |
Total Assets |
555 M | 549 M | 594 M | 504 M | 551 M | 664 M | 789 M | 833 M | 736 M | 808 M | 673 M | 726 M | - | 828 M | 777 M | 775 M | 747 M | 764 M | 607 M | 607 M | 607 M | 607 M | 605 M | 605 M | 605 M | 605 M | 709 M | 709 M | 709 M | 709 M | 520 M | 520 M | 520 M | 520 M | 525 M | 525 M | 525 M | 525 M | 512 M | 512 M | 512 M | 512 M | 135 M | 135 M | 135 M | 135 M | 20.5 M | 20.5 M | 20.5 M | 20.5 M | 2.39 M | 2.39 M | 2.39 M | 2.39 M | 19.6 K | - | - | - |
Cash and Cash Equivalents |
75.2 M | 61.9 M | 58.5 M | 36.4 M | 32.3 M | 43.3 M | 58.2 M | 144 M | 70.9 M | 161 M | 61.7 M | 151 M | 180 M | 257 M | 166 M | 150 M | 83.3 M | 148 M | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 62.4 M | 62.4 M | 62.4 M | 62.4 M | 103 M | 103 M | 103 M | 103 M | 99.4 M | 99.4 M | 99.4 M | 99.4 M | 41 M | 41 M | 41 M | 41 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 6 M | 6 M | 6 M | 6 M | 11 K | 11.4 K | 11.4 K | 11.4 K | 10.1 K | 3.89 K | 3.93 K | - |
Book Value |
32.7 M | 32.8 M | 59.1 M | -30.5 M | 15.1 M | 74.1 M | 201 M | 280 M | 116 M | 189 M | 42.9 M | 101 M | - | 208 M | 302 M | 307 M | 332 M | 363 M | 211 M | 211 M | 211 M | 211 M | 221 M | 221 M | 221 M | 221 M | 318 M | 318 M | 318 M | 318 M | 293 M | 293 M | 293 M | 293 M | 308 M | 308 M | 308 M | 308 M | 300 M | 300 M | 300 M | 300 M | -37.3 M | -37.3 M | -37.3 M | -37.3 M | -19.7 M | -18.3 M | -18.3 M | -18.3 M | -3.41 M | 2.39 M | 2.39 M | -3.41 M | 19.6 K | - | - | - |
Total Shareholders Equity |
32.7 M | 32.8 M | 59.1 M | -30.5 M | 15.1 M | 74.1 M | 201 M | 280 M | 116 M | 189 M | 42.9 M | 101 M | 157 M | 208 M | 302 M | 307 M | 332 M | 363 M | 211 M | 211 M | 211 M | 211 M | 221 M | 221 M | 221 M | 221 M | 318 M | 318 M | 318 M | 318 M | 293 M | 293 M | 293 M | 293 M | 308 M | 308 M | 308 M | 308 M | 300 M | 300 M | 300 M | 300 M | -37.3 M | -37.3 M | -37.3 M | -37.3 M | -19.7 M | -18.3 M | -18.3 M | -18.3 M | -3.41 M | -3.41 M | -3.41 M | -3.41 M | -536 K | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Travere Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.